323 related articles for article (PubMed ID: 25623631)
1. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
[TBL] [Abstract][Full Text] [Related]
2. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
Kitchen S; Kershaw G; Tiefenbacher S
Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
[TBL] [Abstract][Full Text] [Related]
3. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
4. Calibration of the Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) standard for human coagulation factor VIII concentrate for use in the potency assay.
Kirschbaum N; Wood L; Lachenbruch P; Weinstein M; Daas A; Rautmann G; Spieser JM; Buchheit KH
Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):31-64. PubMed ID: 12448031
[TBL] [Abstract][Full Text] [Related]
5. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
6. Calibration of human coagulation factor VIII concentrate Ph. Eur. BRP Batch 4 for use in potency assays.
Raut S; Costanzo A; Daniels S; Heath A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Oct; 2010(2):1-29. PubMed ID: 21144486
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
8. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Kitchen S; Signer-Romero K; Key NS
Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
[TBL] [Abstract][Full Text] [Related]
9. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
[TBL] [Abstract][Full Text] [Related]
10. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
11. Calibration of human coagulation factor VII concentrate Ph. Eur. BRP batch 2.
Dodt J; Costanzo A; Daas A; Hunfeld A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):31-8. PubMed ID: 20223188
[TBL] [Abstract][Full Text] [Related]
12. Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy.
Hubbard AR
Semin Thromb Hemost; 2015 Nov; 41(8):849-54. PubMed ID: 25703515
[TBL] [Abstract][Full Text] [Related]
13. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
15. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
Cauchie M; Toelen J; Peerlinck K; Jacquemin M
Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
[TBL] [Abstract][Full Text] [Related]
16. Calibration of the Ph. Eur. human coagulation Factor VIII concentrate BRP batch 5.
Raut S; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2017; 2017():1-11. PubMed ID: 28279252
[TBL] [Abstract][Full Text] [Related]
17. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
18. Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.
Tierney R; Hockley J; Rigsby P; Terao E; Daas A; Buchheit KH; Sesardic D
Pharmeur Bio Sci Notes; 2011 Jun; 2011(1):1-26. PubMed ID: 21619853
[TBL] [Abstract][Full Text] [Related]
19. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
Peyvandi F; Oldenburg J; Friedman KD
J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
[TBL] [Abstract][Full Text] [Related]
20. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
